Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
171 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hemophilia A - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2014', provides an overview of the Hemophilia A's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hemophilia A - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hemophilia A Overview 8 Therapeutics Development 9 Pipeline Products for Hemophilia A - Overview 9 Pipeline Products for Hemophilia A - Comparative Analysis 10 Hemophilia A - Therapeutics under Development by Companies 11 Hemophilia A - Therapeutics under Investigation by Universities/Institutes 14 Hemophilia A - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Hemophilia A - Products under Development by Companies 18 Hemophilia A - Products under Investigation by Universities/Institutes 21 Hemophilia A - Companies Involved in Therapeutics Development 22 Baxter International Inc. 22 Biogen Idec Inc. 23 AstraZeneca PLC 24 Emergent BioSolutions Inc. 25 Lentigen Corporation 26 Sangamo BioSciences, Inc. 27 Pharming Group N.V. 28 Novo Nordisk A/S 29 Grifols, S.A. 30 BioMarin Pharmaceutical Inc. 31 Chugai Pharmaceutical Co., Ltd. 32 rEVO Biologics 33 Octapharma AG 34 Pfizer Inc. 35 SK Chemicals Co., Ltd. 36 Bayer AG 37 OPKO Health, Inc. 38 ReGenX Biosciences, LLC 39 Alnylam Pharmaceuticals, Inc. 40 Green Cross Corporation 41 Amarna Therapeutics B.V. 42 EpiVax, Inc. 43 Expression Therapeutics LLC 44 Asklepios BioPharmaceutical, Inc. 45 Inserm Transfert SA 46 Selecta Biosciences, Inc. 47 Celtic Pharmaceutical Holdings L.P. 48 Inbiopro Solutions Pvt. Ltd. 49 The International Biotechnology Center (IBC) "Generium" 50 UniQure NV 51 AlphaMab Co., Ltd 52 Dong-A Socio Group 53 Hemophilia A - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Target 55 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 coagulation factor VIII-Fc (recombinant) - Drug Profile 64 BAX-801 - Drug Profile 66 simoctocog alfa - Drug Profile 68 coagulation factor VIIa (recombinant) biosimilar - Drug Profile 70 coagulation factor VIII-Fc (recombinant) - Drug Profile 71 BAX-855 - Drug Profile 73 simoctocog alfa - Drug Profile 74 BAY-818973 - Drug Profile 76 NN-7088 - Drug Profile 78 BAY-949027 - Drug Profile 79 LR-769 - Drug Profile 80 CSL-627 - Drug Profile 82 coagulation factor VIII (recombinant) - Drug Profile 83 coagulation factor VIIa (recombinant) - Drug Profile 84 BAX-801 - Drug Profile 86 CSL-689 - Drug Profile 88 GNR-002 - Drug Profile 90 oprelvekin - Drug Profile 91 coagulation factor VIII (recombinant) - Drug Profile 92 ACE-910 - Drug Profile 93 PF-05280602 - Drug Profile 94 concizumab - Drug Profile 95 ALN-AT3 - Drug Profile 96 eptacog alfa biosimilar - Drug Profile 97 ZFP Transcription Factors for Hemophilia - Drug Profile 98 LG-889 - Drug Profile 99 BAX-826 - Drug Profile 100 coagulation factor VIII (recombinant) - Drug Profile 101 DA-3808 - Drug Profile 102 PEG-rFVIII-PI - Drug Profile 103 MOD-5014 - Drug Profile 104 IBPH-001OC - Drug Profile 106 Human Coagulation Factor-VIII - Drug Profile 107 Deimmunized FVIII - Drug Profile 108 Gene Therapy To Activate Factor VIII For Hemophilia A - Drug Profile 109 Recombinant Protein to Replace Factor VIII for Hemophilia A - Drug Profile 110 Long Acting Coagulation Factor VIIa - Drug Profile 111 ET-3 - Drug Profile 113 BNP-FVIII - Drug Profile 114 SEL-201 - Drug Profile 115 BMN-270 - Drug Profile 116 TheraPEG-FVIII - Drug Profile 117 moroctocog alfa biosimilar - Drug Profile 118 Gene Therapy for Bleeding and Clotting Disorders - Drug Profile 119 coagulation factor VIII (recombinant) - Drug Profile 120 Gene Therapy for Hemophilia A - Drug Profile 121 Gene Therapy for Hemophilia - Drug Profile 122 LG-888 - Drug Profile 123 rhFactor VIII - Drug Profile 124 SVF-VIIa - Drug Profile 125 AZ-10047130 - Drug Profile 126 AZ-10776241 - Drug Profile 127 Hemophilia A - Recent Pipeline Updates 128 Hemophilia A - Dormant Projects 154 Hemophilia A - Discontinued Products 155 Hemophilia A - Product Development Milestones 156 Featured News & Press Releases 156 Appendix 166 Methodology 166 Coverage 166 Secondary Research 166 Primary Research 166 Expert Panel Validation 166 Contact Us 167 Disclaimer 167
List of Tables Number of Products under Development for Hemophilia A, H2 2014 13 Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Hemophilia A - Pipeline by Baxter International Inc., H2 2014 26 Hemophilia A - Pipeline by Biogen Idec Inc., H2 2014 27 Hemophilia A - Pipeline by AstraZeneca PLC, H2 2014 28 Hemophilia A - Pipeline by Emergent BioSolutions Inc., H2 2014 29 Hemophilia A - Pipeline by Lentigen Corporation, H2 2014 30 Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H2 2014 31 Hemophilia A - Pipeline by Pharming Group N.V., H2 2014 32 Hemophilia A - Pipeline by Novo Nordisk A/S, H2 2014 33 Hemophilia A - Pipeline by Grifols, S.A., H2 2014 34 Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 35 Hemophilia A - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 36 Hemophilia A - Pipeline by rEVO Biologics, H2 2014 37 Hemophilia A - Pipeline by Octapharma AG, H2 2014 38 Hemophilia A - Pipeline by Pfizer Inc., H2 2014 39 Hemophilia A - Pipeline by SK Chemicals Co., Ltd., H2 2014 40 Hemophilia A - Pipeline by Bayer AG, H2 2014 41 Hemophilia A - Pipeline by OPKO Health, Inc., H2 2014 42 Hemophilia A - Pipeline by ReGenX Biosciences, LLC, H2 2014 43 Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 44 Hemophilia A - Pipeline by Green Cross Corporation, H2 2014 45 Hemophilia A - Pipeline by Amarna Therapeutics B.V., H2 2014 46 Hemophilia A - Pipeline by EpiVax, Inc., H2 2014 47 Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2014 48 Hemophilia A - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 49 Hemophilia A - Pipeline by Inserm Transfert SA, H2 2014 50 Hemophilia A - Pipeline by Selecta Biosciences, Inc., H2 2014 51 Hemophilia A - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2014 52 Hemophilia A - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 53 Hemophilia A - Pipeline by The International Biotechnology Center (IBC) "Generium", H2 2014 54 Hemophilia A - Pipeline by UniQure NV, H2 2014 55 Hemophilia A - Pipeline by AlphaMab Co., Ltd, H2 2014 56 Hemophilia A - Pipeline by Dong-A Socio Group, H2 2014 57 Assessment by Monotherapy Products, H2 2014 58 Number of Products by Stage and Target, H2 2014 60 Number of Products by Stage and Mechanism of Action, H2 2014 63 Number of Products by Stage and Route of Administration, H2 2014 65 Number of Products by Stage and Molecule Type, H2 2014 67 Hemophilia A Therapeutics - Recent Pipeline Updates, H2 2014 132 Hemophilia A - Dormant Projects, H2 2014 158 Hemophilia A - Discontinued Products, H2 2014 159
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
